학술논문
Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: A phase 1 expansion cohort in patients with relapsed or refractory lymphoma
Document Type
Article
Author
Source
In: Leukemia and Lymphoma . (Leukemia and Lymphoma, 1 June 2015, 56(6):1763-1770)
Subject
Language
English
ISSN
10292403
10428194
10428194